Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program
Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program
复制标题
DOI：
10.1634/theoncologist.12-1-20
复制
发表时间：
2007-01-01
期刊：
影响因子：
5.8
通讯作者：
Edwards, Brenda K.
中科院分区：
文献类型：
--
作者：
Hayat, Matthew J.;Howlader, Nadia;Edwards, Brenda K.
根据监测、流行病学和最终结果计划的数据，概述了选定癌症和所有地点的癌症统计数据和趋势。从1974年到1978年到1999年到2003年，所有部位的平均诊断年龄都增加了2岁。从1975年到2003年，癌症发病率的变化是由联合点回归分析确定的时间段的年变化百分比总结的。在最初的稳定（1975-1979）之后，从1979年到2003年，所有癌症部位的女性发病率都有所增加，尽管最近增长速度有所放缓。对于男性来说，所有癌症部位的发病率最初增加（1975-1992年），随后发病率下降（1992-1995年），1995年至2003年呈稳定趋势。从1981年到2003年，女性甲状腺癌的发病率持续上升。黑人在所有癌症部位的发病率和死亡率都是最高的。根据2001年至2003年的数据，在一个人的一生中患癌症的可能性大约是男性的二分之一，女性的三分之一。所有分期（1996-2002）的5年相对生存率从肺癌患者的16%到前列腺癌患者的100%不等。癌症的存活率因疾病阶段和种族而异，黑人的存活率比白人低。发生多发性原发癌的风险从原发性肝癌的1%到原发性膀胱癌的16%不等。对未来美国癌症负担的影响是根据美国人口的增长和老龄化来估计的。新癌症患者的数量预计将从2000年的136万增加到2050年的近300万。
An overview of cancer statistics and trends for selected cancers and all sites combined are given based on data from the Surveillance, Epidemiology, and End Results Program. Median age at diagnosis for all sites combined shows a 2-year increase from 1974 through 1978 to 1999 through 2003. Changes in cancer incidence rates from 1975 through 2003 are summarized by annual percent change for time periods determined by joinpoint regression analysis. After initial stability (1975-1979), incidence rates in women for all cancer sites combined increased from 1979 through 2003, although the rate of increase has recently slowed. For men, initial increases in all cancer sites combined (1975-1992) are followed by decreasing incidence rates (1992-1995) and stable trends from 1995 through 2003. Female thyroid cancer shows continued increasing incidence rates from 1981 through 2003. Blacks have the highest incidence and mortality rates for men and women for all cancer sites combined. Based on 2001 through 2003 data, the likelihood of developing cancer during one's lifetime is approximately one in two for men and one in three for women. Five-year relative survival for all stages combined (1996-2002) ranges from 16% for lung to 100% for prostate cancer patients. Cancer survival varies by stage of disease and race, with lower survival in blacks compared with whites. The risk of developing subsequent multiple primary cancers varies from 1% for an initial liver primary diagnosis to 16% for initial bladder cancer primaries. The impact on the future U. S. cancer burden is estimated based on the growing and aging U. S. population. The number of new cancer patients is expected to more than double from 1.36 million in 2000 to almost 3.0 million in 2050.